

# Intellectual Property and Access to Medicines in Europe

## Revisiting the Incentives Framework

Wednesday, 16 May, 2018  
9.30–11.30  
European Parliament, Brussels  
Room A3H-1

[Register](#)

Health Action International invites you to a roundtable discussion, with key stakeholders from European Union (EU) institutions and civil society, to share perspectives on the intellectual property (IP) incentives framework and access to medicines in Europe.

### BACKGROUND

High-priced medicines, resulting from the current IP incentives framework, have become an increasingly relevant problem, not only in low- and middle-income countries, but also in high-income ones. As such, there is renewed scrutiny of the impact of IP rights and incentives, and numerous calls to make use of the flexibilities in the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement—and other IP management tools—in containing costs and improving and securing access to medicines in the EU and beyond.

### PROGRAMME

Hosted by Nessa Childers MEP (S&D, ENVI) and José Inácio Faria MEP (EPP, ENVI)

**Opening Remarks:** Jaume Vidal, Policy Advisor, Health Action International

**Roundtable Discussion:** Intellectual Property and Access to Medicines in Europe: Revisiting the Incentives Framework

**Moderator:** Agustín Reyna, Chief Competition Advisor, The European Consumer Organisation (BEUC)

### Interventions:

- Nessa Childers MEP
- José Inácio Faria MEP
- Denis Dambois, Industrial Property and the Fight Against Counterfeiting, European Commission (DG GROW)
- Dr Ellen 't Hoen, IP Rights Expert, Global Health Unit, University Medical Center Groningen; Director, Medicines Law and Policy
- HU Yuan Qiong, Senior Legal and Policy Advisor, Médecins Sans Frontières Access Campaign
- Adrian van den Hoven, Director General, Medicines for Europe

### Open Discussion and Conclusions

[Register](#)